Hero Image

Supplement Technology

An Evidence-Based Revolution in Supplements. The first personalized supplement platform protected by IP, driven by data, and designed to scale like software in a $55B legacy market.

US Market Size

$

0

B

Total Supplement Market Value

CAGR

0

%

Growth Rate of Personalized Supplements

Annual Searches

0

Million

Us Adults Spending $100+ Monthly

We're transforming how supplements are created, delivered, and experienced through cutting-edge technology and scientific precision.

We're transforming how supplements are created, delivered, and experienced through cutting-edge technology and scientific precision.

We're transforming how supplements are created, delivered, and experienced through cutting-edge technology and scientific precision.

The Problem

The Problem

The Problem

The Supplement Industry is Notoriously Confusing

Consumers take supplements but are riddled with doubts. Which supplements are right for me? What brand is right for me? Do I really need these supplements? Do they work?


The confusion comes from a low level of consumer education, virtually no clinical trials, and a perceived lack of regulation meaning consumers often reluctantly make purchasing decisions with low confidence. 


We didn't set out to make another supplement. We built a better system that addresses these fundamental problems through technology, science, and innovation. The supplement industry has failed to evolve despite massive consumer demand for better solutions.

Icon
Overwhelming Choices

29,000+ products on the market with no clear guidance on what actually works.

Icon
Overwhelming Choices

29,000+ products on the market with no clear guidance on what actually works.

Icon
Overwhelming Choices

29,000+ products on the market with no clear guidance on what actually works.

Icon
Low Absorption

Most pills deliver only 10% of their nutrients, wasting money and limiting effectiveness.

Icon
Low Absorption

Most pills deliver only 10% of their nutrients, wasting money and limiting effectiveness.

Icon
Low Absorption

Most pills deliver only 10% of their nutrients, wasting money and limiting effectiveness.

Icon
No Personalization

One-size-fits-all doesn't work for real bodies with unique needs and conditions.

Icon
No Personalization

One-size-fits-all doesn't work for real bodies with unique needs and conditions.

Icon
No Personalization

One-size-fits-all doesn't work for real bodies with unique needs and conditions.

Personalization

Personalization

Personalization

The Perfect Market Moment

US Market Size

$

0

B

Total Supplement Market Value

CAGR

0

%

Growth Rate of Personalized Supplements

Annual Searches

0

Million

Us Adults Spending $100+ Monthly

We're upgrading a broken business category that already commands $55B in U.S. spend alone. This follows the same playbook as companies that transformed coffee, mattresses, razors, and eyeglasses. Investors have waited for a health tech company that could do what vitamins never could. Now, it exists.

Icon

Massive Established Market

$55B U.S. supplement industry with 25M Americans spending $100+/month on supplements that largely fail to deliver results.

Icon

Massive Established Market

$55B U.S. supplement industry with 25M Americans spending $100+/month on supplements that largely fail to deliver results.

Icon

Massive Established Market

$55B U.S. supplement industry with 25M Americans spending $100+/month on supplements that largely fail to deliver results.

Icon

Market Ready for Disruption

Shocking stagnation in delivery, absorption, and personalization creates an opportunity for innovation in a category that hasn't evolved.

Icon

Market Ready for Disruption

Shocking stagnation in delivery, absorption, and personalization creates an opportunity for innovation in a category that hasn't evolved.

Icon

Market Ready for Disruption

Shocking stagnation in delivery, absorption, and personalization creates an opportunity for innovation in a category that hasn't evolved.

Icon

Unique Timing

The convergence of AI capability, wearable adoption, and health data integration creates a perfect window for transformation.

Icon

Unique Timing

The convergence of AI capability, wearable adoption, and health data integration creates a perfect window for transformation.

Icon

Unique Timing

The convergence of AI capability, wearable adoption, and health data integration creates a perfect window for transformation.

Personalization

Personalization

Personalization

The Personalization Gap

The Personalization Gap

The rush to "look personalized" proves demand exists. Despite market demand, no competitor has delivered true personalization due to significant technical barriers. The first company to deliver actual personalization will capture the highest-value segments, with consumer disappointment with pseudo-personalized products creating ready conversion opportunity.

The rush to "look personalized" proves demand exists. Despite market demand, no competitor has delivered true personalization due to significant technical barriers. The first company to deliver actual personalization will capture the highest-value segments, with consumer disappointment with pseudo-personalized products creating ready conversion opportunity.

Process Image 01
Process Image 01
Background Image 01
Background Image 01

Market Signals

Market Signals

Market Signals

Icon

Every major player attempting to appear personalized

Icon

Hundreds of millions invested in personalization claims

Icon

16% CAGR for pseudo-personalized vs. 6% for traditional

Icon

Consumers willing to pay premium prices​

Technical Barriers

Technical Barriers

Technical Barriers

Icon

Algorithmic complexity beyond most companies

Icon

Delivery method limitations with traditional pills

Icon

Lack of integration with biomarker data

Icon

Inability to create customized formulations at scale

Process Image 03
Process Image 03
Background Image 03
Background Image 03

Market Validation

Market Validation

The competitive landscape shows significant consumer interest in personalized supplements. Top competitors by monthly visitors include HUM Nutrition (370,606), Viome (269,584), Cuure (166,000), and Persona Nutrition (106,363).

 

Using a conservative 2% conversion rate, leading competitor Persona Nutrition generates approximately 2,127 new customers per month. This validates market demand and provides benchmarks for our customer acquisition strategy. Smaller competitors like Vous Vitamin (27,910), VitaRx (26,577), and VitaminLab (18,139) also demonstrate the breadth of interest in this category.  And at the same time, none of them are truly personalizing the supplementation of their customers.

Personalization

Personalization

Personalization

The Illusion of Personalization

The Illusion of Personalization

The Illusion of Personalization

What the market currently calls personalization is simply packaging and curation. Competitors aren't creating personalized formulas – they're matching you to pre-made products with no continuous adaptation to your changing body and limited ingredient combinations from pre-determined options.

 

The hard truth is that these aren't personalized systems. They're curated catalogs masquerading as personalized solutions while delivering the same old supplement experience with new marketing.

What the market currently calls personalization is simply packaging and curation. Competitors aren't creating personalized formulas – they're matching you to pre-made products with no continuous adaptation to your changing body and limited ingredient combinations from pre-determined options.

 

The hard truth is that these aren't personalized systems. They're curated catalogs masquerading as personalized solutions while delivering the same old supplement experience with new marketing.

What the market currently calls personalization is simply packaging and curation. Competitors aren't creating personalized formulas – they're matching you to pre-made products with no continuous adaptation to your changing body and limited ingredient combinations from pre-determined options.

 

The hard truth is that these aren't personalized systems. They're curated catalogs masquerading as personalized solutions while delivering the same old supplement experience with new marketing.

User data from wearables

Online user data entry

Home blood test

MLA

Machine Learning Alogrithms

Doctor-Formulated

Patent Granted

Variable Ingredients

Active formula updates

Delivery Mechanism

Children

Paying Customers

Price

(30-day subscription)

Latest Revenue ($m)

Capital Raised ($m)

Icon
Icon
Icon

Icon
Icon

Icon

75

Monthly

Liquid Dropper

Icon
Icon

$149

-

-

Icon
Icon
Icon
Icon
Icon
Icon

51

No

Tablet

Icon
Icon

$66-$132

$24.3M

217.5M

Icon
Icon
Icon
Icon
Icon
Icon

34

No

Granules

Icon
Icon

$150

$3.0M

$22.8M

Icon
Icon
Icon
Icon
Icon
Icon

10

No

Tablet

Icon
Icon

$25-$100

$5.8M

$10.8M

Icon
Icon
Icon
Icon
Icon
Icon

-

No

Tablet

Icon
Icon

$60-$80

$6.8M

$8.0M

Icon
Icon
Icon
Icon
Icon
Icon

-

No

Gummy

Icon
Icon

$55

$6.3M

$17.8M

Features

User data from wearables

Online user data entry

Home blood test

Machine Learning Alogrithms

Doctor-Formulated

Patent Granted

Variable Ingredients

Active formula updates

Delivery Mechanism

Children

Paying Customers

Price

(30-day subscription)

Latest Revenue ($m)

Capital Raised ($m)

Icon
Icon
Icon
Icon
Icon
Icon

75

Monthly

Liquid Dropper

Icon
Icon

$149

-

-

Features

User data from wearables

Online user data entry

Home blood test

Machine Learning Alogrithms

Doctor-Formulated

Patent Granted

Variable Ingredients

Active formula updates

Delivery Mechanism

Children

Paying Customers

Price

(30-day subscription)

Latest Revenue ($m)

Capital Raised ($m)

Icon
Icon
Icon
Icon
Icon
Icon

51

No

Tablet

Icon
Icon

$66-$132

$24.3M

$217.5M

Features

User data from wearables

Online user data entry

Home blood test

Machine Learning Alogrithms

Doctor-Formulated

Patent Granted

Variable Ingredients

Active formula updates

Delivery Mechanism

Children

Paying Customers

Price

(30-day subscription)

Latest Revenue ($m)

Capital Raised ($m)

Icon
Icon
Icon
Icon
Icon
Icon

34

No

Granules

Icon
Icon

$150

$3.0M

$22.8M

Features

User data from wearables

Online user data entry

Home blood test

Machine Learning Alogrithms

Doctor-Formulated

Patent Granted

Variable Ingredients

Active formula updates

Delivery Mechanism

Children

Paying Customers

Price

(30-day subscription)

Latest Revenue ($m)

Capital Raised ($m)

Icon
Icon
Icon
Icon
Icon
Icon

75

Monthly

Liquid Dropper

Icon
Icon

$149

-

-

Features

User data from wearables

Online user data entry

Home blood test

Machine Learning Alogrithms

Doctor-Formulated

Patent Granted

Variable Ingredients

Active formula updates

Delivery Mechanism

Children

Paying Customers

Price

(30-day subscription)

Latest Revenue ($m)

Capital Raised ($m)

Icon
Icon
Icon
Icon
Icon
Icon

51

No

Tablet

Icon
Icon

$66-$132

$24.3M

$217.5M

Features

User data from wearables

Online user data entry

Home blood test

Machine Learning Alogrithms

Doctor-Formulated

Patent Granted

Variable Ingredients

Active formula updates

Delivery Mechanism

Children

Paying Customers

Price

(30-day subscription)

Latest Revenue ($m)

Capital Raised ($m)

Icon
Icon
Icon
Icon
Icon
Icon

34

No

Granules

Icon
Icon

$150

$3.0M

$22.8M

User data from wearables

Online user data entry

Home blood test

Machine Learning Alogrithms

Doctor-Formulated

Patent Granted

Variable Ingredients

Active formula updates

Delivery Mechanism

Children

Paying Customers

Price

(30-day subscription)

Latest Revenue ($m)

Capital Raised ($m)

Icon

Icon
Icon
Icon
Icon
Icon

75

Monthly

Liquid Dropper

Icon
Icon

$149

-

-

Icon

Icon
Icon
Icon
Icon
Icon

51

No

Tablet

Icon
Icon

$66-$132

$24.3M

$217.5M

Icon

Icon
Icon
Icon
Icon
Icon

34

No

Granules

Icon
Icon

$150

$3.0M

$22.8M

User data from wearables

Online user data entry

Home blood test

Machine Learning Alogrithms

Doctor-Formulated

Patent Granted

Variable Ingredients

Active formula updates

Delivery Mechanism

Children

Paying Customers

Price

(30-day subscription)

Latest Revenue ($m)

Capital Raised ($m)

Icon

Icon
Icon
Icon
Icon
Icon

75

Monthly

Liquid Dropper

Icon
Icon

$149

-

-

Icon

Icon
Icon
Icon
Icon
Icon

51

No

Tablet

Icon
Icon

$66-$132

$24.3M

$217.5M

Icon

Icon
Icon
Icon
Icon
Icon

34

No

Granules

Icon
Icon

$150

$3.0M

$22.8M

The Solution

The Solution

The Solution

Our Solution

Our hyper-personalized supplement platform is built on three pillars of innovation. Our AI-powered evidence engine analyzes 14 million peer-reviewed studies to include only ingredients with scientific backing, replacing marketing claims with scientific certainty. Real-time personalization integrates blood tests, wearables & health apps, with formulas evolving with your changing body - no static formulas or base packs.

Our liquid delivery method (US Patent #11,710,551) provides 90% bioavailability versus 10-20% for pills, essential for aging populations and those with GI issues.

The Solution

The Solution

The Solution

True Personalization:
The Supplement Technology Difference

Our approach creates 1.778×10^78 possible combinations – more than atoms in the observable universe. Each ingredient has a full clinical framework built from RCTs, Cochrane reviews, and NIH guidance, including inclusion/exclusion criteria, drug interactions, and optimal dosage forms.

Icon

Formula Creation From Scratchon

Each formula built entirely from scratch monthly based on evolving data - no two formulas are exactly alike

Icon

Formula Creation From Scratchon

Each formula built entirely from scratch monthly based on evolving data - no two formulas are exactly alike

Icon

Formula Creation From Scratchon

Each formula built entirely from scratch monthly based on evolving data - no two formulas are exactly alike

Icon

Clinical-Grade Algorithmic Precision

PubMed-validated analysis with evidence-based inclusion criteria, medical condition-specific dosing, and risk-factor stratification

Icon

Clinical-Grade Algorithmic Precision

PubMed-validated analysis with evidence-based inclusion criteria, medical condition-specific dosing, and risk-factor stratification

Icon

Clinical-Grade Algorithmic Precision

PubMed-validated analysis with evidence-based inclusion criteria, medical condition-specific dosing, and risk-factor stratification

Icon

Comprehensive Ingredient Approach

75+ active ingredients optimized across three delivery systems based on absorption kinetics and synergistic timing

Icon

Comprehensive Ingredient Approach

75+ active ingredients optimized across three delivery systems based on absorption kinetics and synergistic timing

Icon

Comprehensive Ingredient Approach

75+ active ingredients optimized across three delivery systems based on absorption kinetics and synergistic timing

Icon

Continuous Evolution

True closed-loop system with monthly adjustments based on bloodwork changes, wearable data, and seasonal variations

Icon

Continuous Evolution

We prioritize delivering top-notch solutions with a relentless focus on quality, reliability, and customer.

Icon

Continuous Evolution

True closed-loop system with monthly adjustments based on bloodwork changes, wearable data, and seasonal variations

The Solution

The Solution

The Solution

Competitive Advantage

What sets us apart from every competitor is our approach to true personalization. While others offer limited options, we provide 1.778×10^78 possible combinations with monthly algorithm-driven adjustments based on comprehensive health data.

Dynamic Data-Driven Personalization

While competitors rely on static quiz-based approaches, we build formulas from scratch monthly using real-time health data.

Superior Delivery Method Capabilities

Our liquid delivery achieves >90% absorption compared to the 10-20% for traditional.

AI Driven Results

We use AI to isolate the irrefutable evidence in over 14 million scientific papers.

Evidence-Based Formulations

We replace marketing claims with PubMed-Validated clinical research for every ingredient and interaction.

Health Data Integration

Comprehensive integration of blood work and wearables creates a truly responsive system versus limited or no data inegration from competitors.

Dynamic Data-Driven Personalization

While competitors rely on static quiz-based approaches, we build formulas from scratch monthly using real-time health data.

Superior Delivery Method Capabilities

Our liquid delivery achieves >90% absorption compared to the 10-20% for traditional.

AI Driven Results

We use AI to isolate the irrefutable evidence in over 14 million scientific papers.

Evidence-Based Formulations

We replace marketing claims with PubMed-Validated clinical research for every ingredient and interaction.

Health Data Integration

Comprehensive integration of blood work and wearables creates a truly responsive system versus limited or no data inegration from competitors.

Dynamic Data-Driven Personalization

While competitors rely on static quiz-based approaches, we build formulas from scratch monthly using real-time health data.

Superior Delivery Method Capabilities

Our liquid delivery achieves >90% absorption compared to the 10-20% for traditional.

AI Driven Results

We use AI to isolate the irrefutable evidence in over 14 million scientific papers.

Evidence-Based Formulations

We replace marketing claims with PubMed-Validated clinical research for every ingredient and interaction.

Health Data Integration

Comprehensive integration of blood work and wearables creates a truly responsive system versus limited or no data inegration from competitors.

About Image
About Image
About Image
Background Image
Background Image
Background Image

The Solution

The Solution

The Solution

Patent Protection:
Our Competitive Moat

Patent Protection:
Our Competitive Moat

Patent Protection:
Our Competitive Moat

U.S. Patent #11,710,551 (granted July 2023) secures our market position by protecting core aspects of our business: delivery of personalized supplement formulations, algorithm-driven personalization based on biomarkers, real-time adjustment of formulations, and multi-factorial personalization using our specific approach.

 

This forces competitors to use inferior delivery methods or different personalization approaches, creating a clear barrier to entry and enabling premium positioning without immediate price competition.

U.S. Patent #11,710,551 (granted July 2023) secures our market position by protecting core aspects of our business: delivery of personalized supplement formulations, algorithm-driven personalization based on biomarkers, real-time adjustment of formulations, and multi-factorial personalization using our specific approach.

 

This forces competitors to use inferior delivery methods or different personalization approaches, creating a clear barrier to entry and enabling premium positioning without immediate price competition.

Our Technology

Our clinical-grade personalization technology delivers precision at scale, not guesswork. The system includes serum level calibration for optimal dosing, such as Vitamin D based on 25(OH)D level, weight, skin type, and UV exposure.

Icon

Evidence-Based AI Engine

Our proprietary algorithm analyzes 14M peer-reviewed studies to create evidence-based inclusion criteria for all 75+ ingredients, with medical condition-specific dosing based on research.

Icon

Data Integration Platform

Seamlessly integrates blood tests, wearables & health apps to provide risk-factor stratification tailored to individual profiles and categorical adjustments based on age, weight, and medical history.

Icon

Optimized Delivery

Three precisely formulated delivery methods (AM and PM Liquids, Daytime drink powder) with ingredients placed based on dosage capacity, absorption kinetics, and synergistic timing.

Business Model

Our Personalized Health-as-a-Service (HaaS) model delivers exceptional value while maintaining strong unit economics. The subscription-based revenue model includes home delivery of personalized formulas that continuously adapt to changing health needs.

EBITDA growth is targeted at 35% as we scale operations and leverage technology for increased efficiency. This creates a sustainable business with strong profitability potential

All-Inclusive Package

$149/month subscription includes personalized formula, bi-annual blood testing, health app integration, and ongoing updates.

High-Value, High-Margin

Gross margins projected to rise from 45% to 65% over 5 years as automation and volume increase.

Cost Savings

83% cost savings for customers versus buying ingredients separately, creating strong value proposition.

Benefit Image

All-Inclusive Package

$149/month subscription includes personalized formula, bi-annual blood testing, health app integration, and ongoing updates.

High-Value, High-Margin

Gross margins projected to rise from 45% to 65% over 5 years as automation and volume increase.

Cost Savings

83% cost savings for customers versus buying ingredients separately, creating strong value proposition.

Benefit Image

All-Inclusive Package

$149/month subscription includes personalized formula, bi-annual blood testing, health app integration, and ongoing updates.

High-Value, High-Margin

Gross margins projected to rise from 45% to 65% over 5 years as automation and volume increase.

Cost Savings

83% cost savings for customers versus buying ingredients separately, creating strong value proposition.

Benefit Image

A Unique Perspective

A Unique Perspective

Our co-founder and Chief Medical Officer, Dr Jatin Joshi is a former surgeon, and currently a Professor of Surgery specializing in evidence-based medicine.


Like many physicians, Jatin was sceptical about supplements until  he had six foot of his intestines removed as a consequence of his Crohn's disease. This led to multiple complications as he was unable to absorb essential vitamins, minerals etc. 


Faced with a lifetime of supplement infusions, Jatin decided to dedicate himself to addressing the problems in the supplement industry. 


The first question he asked himself: “What if supplements were held to the same evidence standards for safety and efficacy as pharmaceuticals?”

Our co-founder and Chief Medical Officer, Dr Jatin Joshi is a former surgeon, and currently a Professor of Surgery specializing in evidence-based medicine.


Like many physicians, Jatin was sceptical about supplements until  he had six foot of his intestines removed as a consequence of his Crohn's disease. This led to multiple complications as he was unable to absorb essential vitamins, minerals etc. 


Faced with a lifetime of supplement infusions, Jatin decided to dedicate himself to addressing the problems in the supplement industry. 


The first question he asked himself: “What if supplements were held to the same evidence standards for safety and efficacy as pharmaceuticals?”

Experienced in the Supplement Industry

Experienced in the Supplement Industry

Experienced in the Supplement Industry

The Founding Team

Icon

Dr. Jatin Joshi

Chief Technology Officer

Jatin is an Associate Professor at UCL, and a trained Plastic Surgeon. He is the recipient of multiple awards, has published research in numerous academic journals and holds a Masters in Evidence-Based Research from Oxford University.

Icon
Icon
Icon

Scott Perkins

Chief Executive Officer

Scott has extensive experience in Finance, gained at leading Investment Banks and Funds. Over the last 20 years, he built several companies from inception, including a supplement brand launched into >25,000 stores in the US, listed a company on AIM and holds an MBA from London Business School.

Icon
Icon
Icon

Darren Crawford

Chief Operating Officer

Darren has built and led businesses across multiple industries, including hospitality, technology, and supplements in the last 30 years. He has experience in sales, marketing, along with a strong track record in brand building and operations. Over the last 12 years, he founded and scaled two health brands as COO, one of which grew to over 125,000 subscribers and generated $100 million in gross annual revenue.

Icon

Nathaneal Mohr

Chief Marketing Officer

Nathaneal Mohr brings decades of entrepreneurial success to his role. He has successfully built and scaled two supplement companies from the ground up, achieving annual revenues of over $10 million and another at $30 million. Nathaneal's expertise in growth strategy has been instrumental in launching products into competitive markets, driving substantial business growth.

Financial Projections

Our financial projections show strong growth from 5,000 subscribers in 2025 to 250,000 by 2029. Revenue is expected to increase from $3.5M to $250M during this period, with ARPU (Average Revenue Per User) growing from $700 to $1000 as we introduce additional services and optimize pricing.

Gross margins are projected to improve from 45% to 65% as we achieve economies of scale and automation efficiencies. Retention rates are expected to strengthen from 60% to 80% as our product evolves and customer experience improves. EBITDA is forecast to reach $88.5M (35% of revenue) by 2029.

Financial Projections

Our financial projections show strong growth from 5,000 subscribers in

2025 to 250,000 by 2029. Revenue is expected to increase from

$3.5M to $250M during this period, with ARPU (Average Revenue Per User) growing

from $700 to $1000 as we introduce additional services and optimize pricing.

Gross margins are projected to improve from 45% to 65% as we achieve economies of

scale and automation efficiencies. Retention rates are expected to

strengthen from 60% to 80% as our product evolves and customer experience

improves. EBITDA is forecast to reach $88.5M (35% of revenue) by 2029.

Financial Projections

Our financial projections show strong growth from 5,000 subscribers in 2025 to 250,000 by 2029. Revenue is expected to increase from $3.5M to $250M during this period, with ARPU (Average Revenue Per User) growing from $700 to $1000 as we introduce additional services and optimize pricing.

Gross margins are projected to improve from 45% to 65% as we achieve economies of scale and automation efficiencies. Retention rates are expected to strengthen from 60% to 80% as our product evolves and customer experience improves. EBITDA is forecast to reach $88.5M (35% of revenue) by 2029.

Y.E. Subscribers

ARPU*

Revenue

Gross Profit

Gross Margin %

Retention Rate

Customer Acquistion Costs

Marketing Costs

EBITDA

EBITDA %

2025

5,000

$700

$3,500,000

$1,575,000

45%

60%

$70

$350,000

$350,000

10%

2026

30,000

$750

$22,500,000

$11,250,000

50%

65%

$105

$2,955,000

$3,795,000

17%

2027

60,000

$800

$48,000,000

$26,400,000

55%

70%

$150

$7,650,000

$11,550,000

24%

2028

120,000

$900

108,000,000

$64,800,000

60%

75%

$195

$18,570,000

$35,430,000

33%

2029

250,000

$1000

$250,000,000

$162,500,000

65%

80%

$250

$49,000,000

$88,500,000

35%

The Roadmap

The Roadmap

The Roadmap

Go-To-Market Strategy

Go-To-Market Strategy

Q3 2025

Q3 2025

JULY 2025: Beta-Test Tech Platform

AUGUST 2025: Complete MVP Manufacturing Line

SEPTEMBER 2025: Official Product Launch

JULY 2025: Beta-Test Tech Platform

AUGUST 2025: Complete MVP Manufacturing Line

SEPTEMBER 2025: Official Product Launch

1

Process Image 01
Process Image 01
Process Image 01
Background Image 01
Background Image 01
Background Image 01
Process Image 03
Process Image 03
Process Image 03
Background Image 03
Background Image 03
Background Image 03

Q4 2025

Q4 2025

NOVEMBER 2025: Order Automated Production Line

NOVEMBER 2025: Order Automated Production Line

2

Q1 2026

Q1 2026

JANUARY 2026: 5,000 Subscriber Target

FEBURARY-MARCH 2026: Install & Commission Automated Line (30,000 Subscriber Capacity)

JANUARY 2026: 5,000 Subscriber Target

FEBURARY-MARCH 2026: Install & Commission Automated Line (30,000 Subscriber Capacity)

3

Process Image 01
Process Image 01
Process Image 01
Background Image 01
Background Image 01
Background Image 01
Process Image 02
Process Image 02
Process Image 02
Background Image 02
Background Image 02
Background Image 02

Year End 2026

Year End 2026

30,000 Subscriber Target

30,000 Subscriber Target

4

Manufacturing & Scaling

Manufacturing & Scaling

Manufacturing & Scaling

Our manufacturing strategy begins with a hand-made MVP that proves the formulation process while creating natural scarcity in the market. As demand grows, we'll implement automated liquid handling machinery from the life sciences sector to enable rapid scaling without compromising on personalization or quality.

 

This phased approach allows us to validate the product-market fit before making significant capital investments in manufacturing infrastructure, reducing initial risk while preparing for growth.

Our manufacturing strategy begins with a hand-made MVP that proves the formulation process while creating natural scarcity in the market. As demand grows, we'll implement automated liquid handling machinery from the life sciences sector to enable rapid scaling without compromising on personalization or quality.

 

This phased approach allows us to validate the product-market fit before making significant capital investments in manufacturing infrastructure, reducing initial risk while preparing for growth.

Our manufacturing strategy begins with a hand-made MVP that proves the formulation process while creating natural scarcity in the market. As demand grows, we'll implement automated liquid handling machinery from the life sciences sector to enable rapid scaling without compromising on personalization or quality.

 

This phased approach allows us to validate the product-market fit before making significant capital investments in manufacturing infrastructure, reducing initial risk while preparing for growth.

Process Image 01
Process Image 01
Process Image 01
Background Image 01
Background Image 01
Background Image 01

1

Hand-Made MVP

Hand-Made MVP

Initial launch with proven formulation process and limited production capacity creating market scarcity.

Initial launch with proven formulation process and limited production capacity creating market scarcity.

2

Automation Design

Automation Design

Design process for automated liquid handling machinery from life sciences sector already underway.

Design process for automated liquid handling machinery from life sciences sector already underway.

3

Scaled Production

Scaled Production

Implementation of automation technology enabling rapid scaling with consistent quality and personalization.

Implementation of automation technology enabling rapid scaling with consistent quality and personalization.

Investment Opportunity

Investment Opportunity

Investment Opportunity

We are seeking $1 Million Seed Capital to Launch & Derisk

We are seeking $1 Million Seed Capital to Launch & Derisk

Series A Capital ($5-10 Million) in 2026 to accelerate growth & invest in automation.

Series A Capital ($5-10 Million) in 2026 to accelerate growth & invest in automation.

Use of Funds to Derisk the Business:

Use of Funds to Derisk the Business:

Use of Funds to Derisk the Business:

Icon

Develop MVP technology platform

Icon

Establish manufacturing facilities

Icon

Key hires in operations and marketing

Icon

Acquire 5,000 customers for $9M ARR

Icon

Test & refine marketing message, pricing, distribution

Background Image 01
Background Image 01
Logo

An Evidence-Based Revolution in Supplements

© 2025 Supplement Technology LLC.

Logo

An Evidence-Based Revolution in Supplements

© 2025 Supplement Technology LLC.

Logo

An Evidence-Based Revolution in Supplements

© 2025 Supplement Technology LLC.